苯溴马龙与非布司他治疗老年痛风患者的疗效及安全性

发布时间：2018-08-04 18:08

【摘要】：目的探讨非布司他与苯溴马龙治疗老年痛风患者的临床效果及安全性。方法采取前瞻性研究方法,120例老年痛风患者采用随机数字表法分为试验组和对照组各60例。试验组采用非布司他治疗,对照组采用苯溴马龙治疗,两组均连续用药24 w后对比临床效果及实验室指标。结果两组治疗前、治疗6 w、12 w后血尿酸(SUA)水平差异无统计学意义(P0.05)。治疗第24周后,试验组SUA水平显著低于对照组(P0.05);关节疼痛、关节肿胀、关节压痛、关节活动障碍评分、血沉(ESR)、C反应蛋白(CRP)、血清可溶性细胞黏附因子(s ICAM)-1、血清内皮素(ET)-1水平显著低于对照组(P0.05);尿素氮(BUN)、肌酐(Cr)水平显著低于对照组(P0.05)。结论非布司他治疗老年痛风患者的效果优于苯溴马龙,同时对患者的肾功能损害程度更小。
[Abstract]:Objective to investigate the clinical efficacy and safety of fentast and benzyl bromide Ma Long in the treatment of elderly patients with gout. Methods 120 elderly patients with gout were randomly divided into trial group (n = 60) and control group (n = 60). The experimental group was treated with non-burestar and the control group was treated with benzyl bromide Ma Long. The clinical effects and laboratory indexes were compared after 24 weeks of continuous administration of benzene bromide in both groups. Results there was no significant difference in serum uric acid (SUA) levels between the two groups before and after treatment for 6 weeks and 12 weeks (P0.05). After 24 weeks of treatment, the level of SUA in the experimental group was significantly lower than that in the control group (P0.05). The levels of serum soluble cell adhesion factor (s ICAM) -1) and endothelin (ET) 1 (ET) -1) in ESR (ESR) C reactive protein (CRP),) were significantly lower than those in control group (P0.05), and the level of (BUN), creatinine (Cr) in urea nitrogen was significantly lower than that in control group (P0.05). Conclusion the efficacy of fentinastar in the treatment of senile gout patients is better than that of phenylbromine Ma Long, and the renal function is less damaged.
【作者单位】：绵阳市中心医院风湿免疫科;
【基金】：绵阳市痛风及高尿酸血症慢病管理系统构建项目(14Q0063)
【分类号】：R589.7

【相似文献】